Guangzhou Gloria Biosciences Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2016-03-23
- Employees
- 147K
- Market Cap
- -
- Website
- https://www.gloriabio.com
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06514508
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Harbin The First Hospital, Harbin, Hei Longjiang, China
Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 152
- Registration Number
- NCT05978401
- Locations
- 🇨🇳
Shang Hai Pulmonary Hospital, Shanghai, Shanghai, China
Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT05909436
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 424
- Registration Number
- NCT05798819
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China
GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05518318
Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 89
- Registration Number
- NCT03972722
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 293
- Registration Number
- NCT03713905
- Locations
- 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, Beijing, China
Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT03655483
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, Sichuan, China
🇨🇳Tianjin Cancer Hospital, Tianjin, Tianjin, China
🇨🇳Guizhou Cancer Hospital, Guiyang, Guizhou, China
© Copyright 2024. All Rights Reserved by MedPath